Neonc Technologies, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding, Subsidiary
- Established
- 2008-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.neonctech.com
A Study of the Safety, Dosing, and Delivery of NEO100 in Patients with Pediatric Brain Tumors
Phase 1
Not yet recruiting
- Conditions
- Diffuse Midline Glioma, H3 K27M-MutantPediatric Tumor of Brain StemPineocytomaSpinal Cord TumorPediatric Tumor of BrainHigh Grade GliomaPediatric Tumor of CNSChoroid Plexus Carcinoma, Childhood
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Neonc Technologies, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT06357377
Safety and Efficacy of NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1
Recruiting
- Conditions
- Glioblastoma, IDH-wildtypeHead and Neck Squamous Cell CarcinomaMelanomaMerkel Cell CarcinomaMismatch Repair Deficient Solid Malignant TumorMicrosatellite Instability-High Colorectal CancerColorectal CancerMicrosatellite Instability-High Solid Malignant TumorNon-small Cell Lung CancerRenal Cell Carcinoma
- Interventions
- Drug: NEO212 Oral CapsuleDrug: FOLFIRI Protocol
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Neonc Technologies, Inc.
- Target Recruit Count
- 134
- Registration Number
- NCT06047379
- Locations
- 🇺🇸
Precision NextGen Oncology, Beverly Hills, California, United States
🇺🇸Northwest Medical Specialties, Tacoma, Washington, United States
NEO100 and High-Grade Meningioma
Phase 2
Recruiting
- Conditions
- Residual, Progressive or Recurrent Grade II or III Meningioma
- Interventions
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Neonc Technologies, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05023018
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- First Posted Date
- 2016-03-10
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Neonc Technologies, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT02704858
- Locations
- 🇺🇸
Northwell Health, New York, New York, United States
🇺🇸Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
🇺🇸Atlantic Health (Overlook Medical Center), Summit, New Jersey, United States
© Copyright 2025. All Rights Reserved by MedPath